CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Non-invasive fetal RHD genotyping: A Rapid Qualitative Review

Last updated: June 27, 2019
Project Number: RC1106-000
Product Line: Rapid Response
Research Type: Devices and Systems
Report Type: Summary with Critical Appraisal
Result type: Report


  1. What is the meaning and impact of noninvasive fetal RhD blood group genotyping for pregnant people, and their health care providers?
  2. What are pregnant peoples’, and their health care providers’, expectations of noninvasive fetal RhD blood group genotyping, and the results of such tests?
  3. How do patients and clinicians make decisions related to noninvasive fetal RhD blood group genotyping, and how do they make decisions based on the results?
  4. How does the option, or not, of noninvasive fetal RhD blood group genotyping help to shape pregnant peoples’ and their health care providers’ experiences and perceptions of pregnancy and its care?

Key Message

Pregnant people and health care providers find fetal RhD genotyping beneficial and feel it should be offered to all RhD negative pregnant persons.   While fetal RhD genotyping is considered beneficial, there is residual concern around the identification of false negatives leading some people to prefer to receive anti-D immunoglobulin despite their test result.   Pregnant people often experience information overload throughout pregnancy and appreciate when information on fetal RhD genotyping can be taken home in the form of informational pamphlets.